- 74 Downloads
Triflusal (Aflen®, Disgren®, Tecnosal®, Triflux®) is a novel platelet antiaggregant with structural similarities to salicylates, but which is not derived from aspirin. It has similar efficacy to aspirin in patients with cerebral or myocardial infarction, but has a reduced risk of haemorrhagic complications. In addition, triflusal plus moderate-intensity anticoagulation has demonstrated efficacy when used as thromboprophylaxis in atrial fibrillation. As such, triflusal has a role in the primary prevention of cerebrovascular events in atrial fibrillation, and for the secondary prevention of cerebral and myocardial infarction, primarily as an alternative to aspirin in patients for whom aspirin is unsuitable.
Triflusal and its principal metabolite, 2-hydroxy-4-(trifluoromethyl)benzoic acid (HTB), inhibit cyclo-oxygenase (COX) isoform 1 and therefore inhibit thromboxane biosynthesis. In addition, both triflusal and HTB inhibit cyclic adenosine monophosphate (cAMP) phosphodiesterase, thereby restricting cAMP breakdown in platelets and also restricting calcium mobilisation and calcium-dependent platelet aggregation. Triflusal appears to have a selective activity against platelet COX-1 relative to vascular endothelial COX-2.
After oral administration, triflusal is rapidly hydrolysed to HTB. After a single dose of 900mg in healthy volunteers, values for absorption half-life of 0.40 and 2.44 hours were documented for triflusal and HTB, respectively. Corresponding values for mean maximum plasma concentration were 11.6 and 92.7 mg/L, and for terminal elimination half-life were 0.53 and 34.3 hours. Triflusal elimination is primarily renal: >60% of the parent compound is excreted in the urine, as unchanged triflusal, HTB and an HTB-glycine conjugate, within 48 hours of administration. There are no major differences in the pharmacokinetic profiles of triflusal and HTB in elderly and younger individuals, such that triflusal dosage adjustments are unnecessary in elderly patients.
In large-scale, randomised, double-blind, multicentre studies in patients with nondisabling ischaemic stroke or a transient ischaemic attack (TLA) in the previous 6 months, triflusal 600 mg/day was equally as effective as aspirin 300–330 mg/day, as evident from the incidence of the primary composite endpoint of serious vascular events (12.7–19.8% vs 12.4–28.8%).
The TIM (Triflusal in Myocardial Infarction) study also revealed no significant triflusal-aspirin difference in occurrence of the composite primary endpoint of death, nonfatal myocardial reinfarction and nonfatal cerebrovascular events within 35 days of acute myocardial infarction (9.1% vs 10.2%). Subgroup analyses of TIM study data suggested that triflusal may be a superior therapeutic option to aspirin in elderly patients receiving concurrent therapy with either alteplase (recombinant tissue plasminogen activator) or an ACE inhibitor; however, this possibility requires further investigation.
In patients with nonvalvular or valvular atrial fibrillation, triflusal plus reduced-intensity acenocoumarol therapy (target international normalised ratio [INR] 1.25–2.4) was significantly more effective than monotherapy with either triflusal or standard-intensity acenocoumarol (target INR 2.0–3.0) regarding a lower incidence of the composite primary endpoint of vascular death, TIA, and nonfatal stroke or systemic embolism; this applied even in patients at high risk of developing thromboembolism.
A randomised, multicentre pilot study of triflusal versus standard-intensity acenocoumarol therapy in patients who had undergone bioprosthetic valve replacement found no significant primary endpoint difference between the two treatments, and triflusal was associated with a significantly lower incidence of haemorrhagic adverse events than acenocoumarol.
Large-scale clinical trials reported that, with the exception of a significantly lower rate of haemorrhagic events in triflusal recipients (e.g. 13.7% vs 21.8%; p < 0.001 in the TACIP [Triflusal versus Aspirin in Cerebral Infarction Prevention] study), the tolerability profile of triflusal was generally similar to that of aspirin. These trials documented a treatment withdrawal rate due to adverse events of 2.3–5.1% in triflusal recipients and of 3.0–6.0% in aspirin recipients. The overall incidence of treatment-related adverse events was 34–54% in both groups. In the largest trial, the TIM study, the main triflusal-induced adverse events involved the gastrointestinal tract (26.8% of patients; primarily dyspepsia, constipation and flatulence) and central and peripheral nervous systems (8.9%; e.g. headache), with no significant difference in incidence rates relative to aspirin recipients. In the second-largest trial (TACIP), the most frequently reported nonhaemorrhagic adverse events in triflusal-treated patients were dyspepsia (27.4%), abdominal pain (21.8%), nausea (8.5%) and vomiting (5.1%).
A large meta-analysis of five studies found no significant difference between triflusal and aspirin in the overall incidence of adverse events (55.3% vs 55.6%), whereas serious treatment-related adverse events were significantly less frequent (4.0% vs 5.2%; p = 0.03), and nonhaemorrhagic gastrointestinal adverse events significantly more frequent (44.0% vs 40.1%; p = 0.004), in triflusal than in aspirin recipients.
Bleeding complications were consistently less common, in large-scale clinical trials and a large meta-analysis, in patients treated with triflusal rather than aspirin. For instance, significantly (p < 0.05) lower rates of the following haemorrhagic complications were evident: CNS-related bleeding in the TIM study (0.3% vs 1.0%); haematoma (3.8% vs 6.7%), gastrointestinal (4.6% vs 7.6%) or any bleeding (13.7% vs 21.8%) in the TACIP study; and bleeding-related adverse events (8.5% vs 13.3%), fatal or nonfatal haemorrhagic stroke (0.5% vs 1.1%), nonfatal haemorrhagic stroke (0.2% vs 0.6%), intracranial or other major extracranial bleeding (1.2% vs 3.0%), any major extracranial bleeding (0.7% vs 1.8%), and any minor (7.6% vs 11.2%) or gastrointestinal bleeding (2.4% vs 4.3%) in a large meta-analysis.
KeywordsAspirin Atrial Fibrillation Acute Myocardial Infarction Dipyridamole Alteplase
- 1.American College of Cardiology and American Heart Association. ACC/AHA/ESC pocket guidelines: management of patients with atrial fibrillation [online]. Available from URL: http://www.acc.org [Accessed 2005 Oct 28]
- 2.Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004 Jun; 57(6): 798–806Google Scholar
- 6.Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004 Aug 3; 110(5): 588–636PubMedCrossRefGoogle Scholar
- 8.Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003 Jan; 24(1): 28–66Google Scholar
- 10.Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002 Oct 2; 40(7): 1366–74PubMedCrossRefGoogle Scholar
- 18.Cruz-Fernandez JM, Lopez G-Aranda V, Montoya FM, et al. Managing acute myocardial infarction: clinical implications of the TIM study. Eur Heart J Suppls 1999; 1 Suppl. F: F12–18Google Scholar
- 19.Culebras A. Triflusal: an effective antiplatelet agent with significantly lower hemorrhagic risk than ASA. Todays Ther Trends 2001; 19(4): 271–81Google Scholar
- 21.Cruz-Fernández JM. Antiplatelet drugs in the treatment of acute coronary syndromes: focus on cyclooxygenase inhibitors. European Heart Journal Suppls 2001 Aug; 3 Suppl. I: 123–30Google Scholar
- 22.J. Uriach & Cia, SA. Triflusal: summary of product characteristics. Barcelona, Spain. 2003Google Scholar
- 24.Dalla-Volta S. Pharmacological basis of antiplatelet drugs in acute myocardial infarction: focus on triflusal. Eur Heart J Suppls 1999; 1 Suppl. F: F7–11Google Scholar
- 26.Albors M, de Castellarnau C, Vila L, et al. Inhibition of thromboxane production and platelet function by triflusal in healthy volunteers. Rev Farmacol Clin Exp 1987; 4(1): 11–6Google Scholar
- 28.Sánchez de Miguel L, Millás I, Garcia-Durán M, et al. New mechanisims for the antiaggregating platelet effects of triflusal: role of nitric oxide and neutrophils [abstract no. 241]. Eur Heart J 1997; 18 Suppl.: 19Google Scholar
- 31.Alvarez-Sabín J, Chacon P, Molina CA, et al. Triflusal is superior to aspirin suppressing the inflammatory response that follows ischemic stroke [abstract no. 24]. Cerebrovasc Dis 2004; 17 Suppl. 5: 109Google Scholar
- 37.Prietro MA, De La Cruz JP, Del Prado MF, et al. Influence of triflusal on platelet activation after coronary artery bypass graft. Blood Coagul Fibrinolysis 2000 Mar; 11: 191–7Google Scholar
- 42.González-Correa JA, Arrebola MM, Ureña IM, et al. Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids. Naunyn Schmiedebergs Arch Pharmacol 2005 Jan; 371(1): 81–8PubMedCrossRefGoogle Scholar
- 48.Whitehead S, Cheng G, Hachinski V, et al. Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity. II. Effects of triflusal. Stroke 2005 Aug; 36(8): 1782–9Google Scholar
- 53.Matias-Guiu J, Ferro JM, Alvarez-Sab’in J, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP study: a randomized, double-blind, multicenter trial. Stroke 2003; 34: 840–8Google Scholar
- 55.Smirne S, Ferini-Strambi L, Cucinotta D, et al. Il triflusal nella prevenzione degli accidenti cerebrovascolari. G Gerontol 1995; 43(10): 563–9Google Scholar
- 57.Smirne S, Ferini-Strambi L, Cucinotta D, et al. Triflusal and prevention of cerebrovascular attacks: double-blind clinical study vs ASA [abstact no. 53]. J Neurol 1994 Jun; 241: S130Google Scholar
- 58.Costa J, Ferro JM, Matias-Guiu J, et al. Triflusal for preventing serious vascular events in people at high risk (review). Cochrane Database Syst Rev 2005; (3): CD004296Google Scholar
- 63.López Bescós L, O’Callaghan AC, Castro-Beiras A, et al. Incidence of vascular stroke in patients with acute myocardial infarction receiving fibrinolytic treatment. Eur Heart J Suppls 1999; 1 Suppl. F: F19–23Google Scholar
- 64.Garcia-Dorado D, Velasco Rami J, Virgós Lamela A, et al. Interaction between antiplatelet agents and ACE inhibitors in patients with acute myocardial infarction. Eur Heart J Suppls 1999; 1 Suppl. F: F24–28Google Scholar
- 67.De la Cruz G, Sorio F, Pérez I, et al. Estudio de seguridad del triflusal, en pacientes asmaticos con intolerancia idiosincratica a aspirina y/o AINEs [abstract]. XVIII Congresco Nacional de la Sociedad Espanoloa de Farmacologia Clinica; 2002 Oct 17–19; Navarra. Rev Med Univ Navarra 2002, 14Google Scholar
- 70.Pontes C, Pérez J, Ríos J, et al. Aspirin but not triflusal increased antihypertensive therapy requirements during long term antiplatelet treatment [abstract no. 304]. Pharmacol Toxicol 2001; 89 Suppl. 1:79Google Scholar
- 71.Fernández De Arriba A, Sanchez Crespo M, Cavalcanti F, et al. Comparative effects of triflusal and aspirin on cardiovascular inflammatory mediators upregulated by NF-kB. XXI Congress of the European Society of Cardiology; 1999 Aug 28–Sep1; Barcelona, 303–9Google Scholar
- 75.Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. N Engl J Med 2001; 345: 494–502Google Scholar
- 76.Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996 Nov; 143: 1–13Google Scholar
- 78.Culebras A. GPIIB/IIIA antagonists and triflusal. IJCP 2003 Apr; 136 Suppl.: 11–4Google Scholar